TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29608768
Drug: Crushed intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed intranasal oxycodone ARIR
Study: 15198118
Drug: Aromatherapy massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy massage (weekly for four weeks)
Study: 11285662
Drug: Mass treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass treatment of all children
Study: 11285662
Drug: Targeted treatment
Normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatment of clinically active children and their household members
Study: 22035502
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in the patient's home
Study: 22035502
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in GP surgeries
Study: 18667247
Drug: Intensive Treatment
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Treatment (Atorvastatin 80 mg immediately after admission)
Study: 18667247
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (Atorvastatin 20 mg from the day of discharge)
Study: 16556892
Drug: HDC/IL-2 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDC/IL-2 treatment (10 cycles of IL-2 at 16,400 U/kg and HDC at 0.5 mg, administered subcutaneously twice daily)
Study: 12875348
Drug: A-Cnotren/Pharmaten, Athens,
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-Cnotren/Pharmaten, Athens, Greece (test preparation)
Study: 8678384
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenges (13.3 mg of zinc from zinc gluconate, one lozenge every 2 hours while awake)
Study: 8678384
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (5% calcium lactate pentahydrate, one lozenge every 2 hours while awake)
Study: 1840138
Drug: Paroxetine co-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine co-treatment for 16 days after a 7-day placebo treatment
Study: 1840138
Drug: Paroxetine co-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine co-treatment
Study: 6121568
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate 6 mg
Study: 6121568
Drug: Methadone 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 6 mg
Study: 6121568
Drug: Pethidine 60
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 60 mg
Study: 17403074
Drug: PEG laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG laxative (17 g daily)
Study: 17403074
Drug: PEG treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG treatment weeks
Study: 17403074
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment weeks
Study: 3757441
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium diet (1800 mg of calcium/day)
Study: 3757441
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium diet (200 mg of calcium/day)
Study: 23710881
Drug: Usual practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual practice of pharmacological emesis prevention (ondansetron 8 mg)
Study: 20470796
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) regimen
Study: 20470796
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) regimen
Study: 18241082
Drug: Adaptive design
Normalized name: Designer Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive design for dose-response trials
Study: 10770216
Drug: rhIGF‐I (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (60 microg/kg, sc, twice daily)
Study: 8867568
Drug: Trandolapril (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2-4 mg once-daily)
Study: 1732769
Drug: High-osmolality contrast
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-osmolality contrast agent (Hypaque 76)
Study: 1732769
Drug: Low-osmolality contrast
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-osmolality contrast agent (Omnipaque 350)
Study: 26940805
Drug: ABT-126 10
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 10 mg
Study: 26940805
Drug: ABT-126 25
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 25 mg (nonsmokers)
Study: 17972024
Drug: EAP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAP regimen (doxorubicin 40 mg/m², etoposide 360 mg/m², cisplatin 80 mg/m² every 28 days)
Study: 17972024
Drug: HD 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HD 5-FU (5-FU 2.6 g/m² 24 h infusion, biweekly)
Study: 16898538
Drug: Selective alpha1-blocker
Normalized name: NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective alpha1-blocker (doxazosin)
Study: 16898538
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy and rehabilitation
Study: 14653830
Drug: Metronidazole 250
Normalized name: metronidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 250 mg t.d.s. for 10 days (Group A)
Study: 14653830
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.d. for 10 days (Group B)
Study: 10794751
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of intravenous ibandronate
Study: 8799771
Drug: Environmental noises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental noises (e.g., baby's crying)
Study: 1634646
Drug: Nisoldipine 30
Normalized name: nisoldipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 30 mg
Study: 31673354
Drug: Alcohol-based hand
Normalized name: ALCOHOL 300 mL in 500 mL EXTRACORPOREAL GEL [JINHUI Alcohol-Based Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-based hand rub (ABHR) gel
Study: 24277644
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administered at 2 hours post-dose
Study: 24277644
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administered at 6 hours post-dose
Study: 24277644
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administered at 2 or 6 hours post-dose
Study: 18815591
Drug: Ritonavir 20
Normalized name: ritonavir 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 20 mg
Study: 18575010
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.5 mg/ml) applied intra- and postoperatively for 5 minutes
Study: 17212078
Drug: Conventional cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cavity preparation
Study: 10102460
Drug: Melagatran (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melagatran (low dose)
Study: 10102460
Drug: Melagatran (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melagatran (medium dose)
Study: 10102460
Drug: Melagatran (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melagatran (high dose)
Study: 2348224
Drug: liposome‐encapsulated doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposome‐encapsulated doxorubicin (LED) at 30 mg/m2
Study: 2348224
Drug: liposome‐encapsulated doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposome‐encapsulated doxorubicin (LED) at 45 mg/m2
Study: 2348224
Drug: liposome‐encapsulated doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposome‐encapsulated doxorubicin (LED) at 60 mg/m2
Study: 2348224
Drug: liposome‐encapsulated doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposome‐encapsulated doxorubicin (LED) at 90 mg/m2
Study: 375768
Drug: Dantrolene (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dantrolene (100-150 mg)
Study: 31250168
Drug: Intrarectal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal instillation of 2% lidocaine gel (group A)
Study: 28510574
Drug: High initial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High initial dosage (10 vials) of Indian polyvalent antivenom
Study: 28510574
Drug: Low initial
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low initial dosage (2 vials) of Indian polyvalent antivenom
Study: 23442273
Drug: Daily Nonlinear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Nonlinear Periodized (DNLP) training
Study: 21168464
Drug: RIS oral
Normalized name: Feoris Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIS oral solution (mean dose, 3.7 mg)
Study: 21168464
Drug: RIS standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIS standard tablets (mean dose, 3.7 mg)
Study: 21168464
Drug: RIS oral
Normalized name: Feoris Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIS oral solution
Study: 21168464
Drug: RIS standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIS standard tablets
Study: 21168464
Drug: Both RIS
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both RIS oral solution and RIS standard tablets
Study: 7618022
Drug: Zolpidem 7.5
Normalized name: zolpidem 7.5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 7.5 mg
Study: 7618022
Drug: Zolpidem 7.5
Normalized name: zolpidem 7.5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 7.5 mg and 10 mg
Study: 30301734
Drug: 17β-estradiol transdermal
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17β-estradiol transdermal patch continuously with cyclic oral micronised progesterone (PATCH)
Study: 30476179
Drug: Combined ethinyl
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined ethinyl estradiol and desogestrel pill (PILL)
Study: 10978851
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplements (ODS) pre- and postoperatively
Study: 10978851
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplements (ODS) preoperatively only
Study: 10978851
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplements (ODS) postoperatively only
Study: 10978851
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral dietary supplements (Control group)
Study: 1681563
Drug: Abecarnil 3-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil 3-9 mg/day
Study: 1681563
Drug: Abecarnil 15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil 15-30 mg/day and 7.5-15 mg/day
Study: 6130080
Drug: buspirone, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone, 20 mg/day
Study: 6130080
Drug: diazepam, 20
Normalized name: DiazePAM, 20 mg rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam, 20 mg/day
Study: 6130080
Drug: clorazepate, 23
Approvals — FDA: no, EMA: no, PMDA: no
Description: clorazepate, 23 mg/day
Study: 26271173
Drug: 13-valent polysaccharide
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent polysaccharide conjugate vaccine (PCV13)
Study: 18947396
Drug: Lipoplus 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoplus 20% (50% MCT, 40% LCT, 10% omega‐3) administered at a dose of 0.12 g/kg/h for 12 hours
Study: 18947396
Drug: Intralipid Fresenius
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid Fresenius Kabi (100% LCT) administered at a dose of 0.12 g/kg/h for 12 hours
Study: 15833501
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) 300 mg
Study: 15833501
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) 600 mg
Study: 15833501
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) 900 mg
Study: 11791087
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogen 0.625 mg and medroxyprogesterone acetate 2.5 mg per day
Study: 11791087
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of oral conjugated estrogen
Study: 11791087
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (control group)
Study: 11791087
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (full and reduced dose)
Study: 10527987
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment time (standard IVF procedure)
Study: 1066813
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (0.2% chlorhexidine gluconate) used 3 times a day for 6 weeks
Study: 1066813
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution (various concentrations: 0.05%, 0.1%, 0.15%, 0.2%) rinsed twice a day for 7 days
Study: 21443986
Drug: Q-500 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-500 (500 mg quercetin, 125 mg vitamin C, and 5 mg niacin)
Study: 21443986
Drug: Q-1,000 (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-1,000 (1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin)
Study: 19577483
Drug: Soy group
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy group (28 g/day textured soy flour for 8 weeks)
Study: 12860500
Drug: No pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacologic treatment (Control)
Study: 9583728
Drug: High pre-treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pre-treatment S-VEGF (>527 pg/ml)
Study: 9583728
Drug: Low pre-treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pre-treatment S-VEGF (n = 17, 25% of all patients)
Study: 2573208
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg q12h
Study: 2573208
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg q6h or q12h
Study: 31045789
Drug: Serratus plane
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus plane block (SPB) with 20 ml of 0.375% ropivacaine
Study: 24502880
Drug: GDF-15 >1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDF-15 >1800 ng/L
Study: 24502880
Drug: GDF-15 <1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDF-15 <1200 ng/L
Study: 22410599
Drug: Short-term life
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term life review (60 minutes, twice a week)
Study: 20453155
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups underwent identical physical therapy training (3 sessions a week for 4 weeks)
Study: 9461369
Drug: salbutamol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol (0.25 ml Ventolin 0.5%)
Study: 9461369
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide (0.25 ml Atrovent 0.025%)
Study: 9461369
Drug: none (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: none (routine administration of bronchodilators)
Study: 2651951
Drug: Slow channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow channel calcium entry blocker (Ca antagonist)
Study: 23127158
Drug: Localized radiofrequency
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized radiofrequency heat (RFH) therapy
Study: 19523421
Drug: DHAD injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHAD injection
Study: 8783218
Drug: Hypnotic obstruction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic obstruction of the left visual field
Study: 8783218
Drug: Hypnotic obstruction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic obstruction of the right visual field
Study: 8783218
Drug: Hypnotic obstruction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic obstruction
Study: 1740583
Drug: Honeybee venom
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honeybee venom immunotherapy (VIT)
Study: 1740583
Drug: Yellow jacket
Normalized name: venom-yellow jacket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow jacket venom immunotherapy (VIT)
Study: 6326999
Drug: Combined radiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiotherapy and chemotherapy (4200 rad)
Study: 6326999
Drug: Combined radiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiotherapy and chemotherapy (3000 rad)
Study: 31902373
Drug: Whole raw
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole raw Gala apples (approximately 200 g)
Study: 31150780
Drug: Placebo conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo conditioning with instrumental control over treatment administration
Study: 31150780
Drug: Standard passive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard passive placebo conditioning without any control over treatment administration
Study: 29340524
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control group (no treatment)
Study: 24673044
Drug: Auricular points
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auricular points group (magnetic-ball sticking therapy)
Study: 16633709
Drug: Corticosteroid +
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid + anesthetic agent injection
Study: 10397617
Drug: Fast dissolving
Normalized name: Mucinex Sinus-Max Day/Night Fast Dissolving Gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast dissolving reference formulation
Study: 10397617
Drug: Hypothetical slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical slow dissolving test formulation
Study: 6353428
Drug: Oxymetazoline (0.025%)
Normalized name: Oxymethazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline (0.025%) ophthalmic solution
Study: 6353428
Drug: Naphazoline (0.04%)
Normalized name: naphazoline 0.0004 MG/MG
DrugBank: Naphazoline (DB06711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naphazoline (0.04%) solution
Study: 31469749
Drug: Fractional ablative
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional ablative CO2 laser treatment
Study: 29665830
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus a brief GOH-based intervention (CT-GOHT)
Study: 16606646
Drug: Sulfasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine (SSZ) 2 g/day
Study: 11153633
Drug: Hypothermic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic group (n = 15), cooled to 32 to 33 degrees C after administration of vecuronium, midazolam, and buprenorphine.
Study: 11153633
Drug: Normothermic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic group (n = 11), body temperature controlled at 36 to 37 degrees C with the same treatment as hypothermic group.
Study: 9100038
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 to 600 mg/d plus prednisone 2.5 mg/d
Study: 23900984
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol using intermittent bolus technique
Study: 23900984
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol using continuous infusion
Study: 24336997
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) program
Study: 21050553
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dinoprostone suppository and ethacridine
Study: 18437172
Drug: Various compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various compounds targeting MAPK pathway